[Treatment of severe refractory pemphigus vulgaris with rituximab]
- PMID: 16540052
- DOI: 10.1016/s0001-7310(06)73348-8
[Treatment of severe refractory pemphigus vulgaris with rituximab]
Abstract
Pemphigus vulgaris is a potentially fatal autoimmune bullous disease. High doses of immunosuppressive drugs are used in managing severe cases of pemphigus. Rituximab, an anti-CD20 monoclonal antibody, has proven to be effective in patients with refractory pemphigus vulgaris and pemphigus foliaceus. We review cases of pemphigus vulgaris and pemphigus foliaceus not associated with lymphoma that were treated with rituximab, and we report a new case of severe refractory pemphigus vulgaris successfully treated with rituximab.
Comment in
-
[Pemphigus vulgaris treated with rituximab].Actas Dermosifiliogr. 2006 Apr;97(3):221-2. doi: 10.1016/s0001-7310(06)73387-7. Actas Dermosifiliogr. 2006. PMID: 16796975 Spanish. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical